<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03033537</url>
  </required_header>
  <id_info>
    <org_study_id>2016</org_study_id>
    <nct_id>NCT03033537</nct_id>
  </id_info>
  <brief_title>Intracavernosal Injection of Papaverine/Verapamil Versus Papaverine/Phentolamine in Erectile Dysfunction</brief_title>
  <official_title>Intracavernosal Injection of Papaverine/Verapamil Versus Papaverine/Phentolamine in Erectile Dysfunction: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adam International Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adam International Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Erectile dysfunction is a common condition with a significant effect on quality
      of life. Verapamil is calcium channel blocker of the phenyl alkylamine class which relaxes
      the tone of the smooth muscles lining blood vessels, leading to their dilatation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: Evaluating the effect of intracavernosal injection of (Papaverine + Verapamil) and
      comparing it with (Papaverine + Phentolamine) in patients with erectile dysfunction.

      Patients and methods: Each one of the 20 erectile dysfunction patients was subjected to
      intracavernosal injection with (30mg Papaverine + 1mg Phentolamine), where penile duplex &amp;
      clinical evaluation was carried out followed by a wash out interval of 2 weeks after which
      each patient was subjected to the exact previous procedures using (30 mg Papaverine + 5 mg
      Verapamil).

      Keywords: Erectile dysfunction - Intracavernosal injection - Penile duplex - Phentolamine -
      Verapamil.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2015</start_date>
  <completion_date type="Actual">January 20, 2016</completion_date>
  <primary_completion_date type="Actual">January 1, 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>IIEF5</measure>
    <time_frame>6 months</time_frame>
    <description>Questionnaire</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Verapamil</arm_group_label>
    <description>Intracavernosal injection of Verapamil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phentolamine</arm_group_label>
    <description>Intracavernosal injection of Phentolamine to treat erectile dysfunction for a period of 2 wweks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <description>Local treatment of erectile dysfunction</description>
    <arm_group_label>Verapamil</arm_group_label>
    <arm_group_label>Phentolamine</arm_group_label>
    <other_name>Calcium Channel Blocker</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Males complaining of erectile dysfunction
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Married male patients suffering from erectile dysfunction and scheduled for
             intracavernosal injection.

        Exclusion Criteria:

          -  Responders to PDE5-inhibitors; congenital or acquired penile anomalies; uncontrolled
             medical conditions or known hypersensitivity to verapamil; Peyronie's disease and any
             known bleeding or coagulation disorders.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2017</study_first_submitted>
  <study_first_submitted_qc>January 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2017</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Adam International Hospital</investigator_affiliation>
    <investigator_full_name>Ahmad Raef Sadek</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
    <mesh_term>Papaverine</mesh_term>
    <mesh_term>Phentolamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

